DROSPIRENONE AND ESTRADIOL
Clinical safety rating: avoid
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity; estradiol is an estrogen. Drospirenone acts as a progesterone receptor agonist, inhibits ovulation, and increases cervical mucus viscosity. Estradiol replaces endogenous estrogen, suppresses gonadotropin secretion.
| Metabolism | Drospirenone is extensively metabolized by cytochrome P450 3A4 (CYP3A4) to inactive metabolites. Estradiol is primarily metabolized in the liver via CYP1A2 and CYP3A4 to estrone and estriol, and undergoes enterohepatic recirculation. |
| Excretion | Drospirenone: ~40-50% renal, ~50-60% fecal; estradiol: ~60-80% renal (as metabolites), ~20-40% fecal. |
| Half-life | Drospirenone: ~30-40 hours (allows once-daily dosing); estradiol: ~12-15 hours (after oral administration). |
| Protein binding | Drospirenone: ~95-97% bound (mostly to albumin, not SHBG); estradiol: ~98% bound (to SHBG and albumin). |
| Volume of Distribution | Drospirenone: ~2.5-3.5 L/kg (large, extensive tissue distribution); estradiol: ~1-2 L/kg. |
| Bioavailability | Oral drospirenone: ~75-85% (due to first-pass metabolism); oral estradiol: ~5-10% (extensive first-pass; micronized estradiol). |
| Onset of Action | Oral: Onset of contraceptive effect after 7 days of continuous use; onset of hormone replacement effect within 2-3 weeks. |
| Duration of Action | 24 hours; sustained contraceptive effect requires daily dosing; continuous use without breaks for extended cycles. |
One tablet (drospirenone 3 mg / estradiol 0.5 mg) orally once daily for hormone therapy.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²) due to risk of hyperkalemia. No dose adjustment for mild to moderate impairment (eGFR 30-89 mL/min/1.73 m²); use with caution and monitor potassium. |
| Liver impairment | Contraindicated in Child-Pugh C (severe hepatic impairment). Not recommended in Child-Pugh B (moderate impairment) as safety not established. Use with caution in Child-Pugh A (mild impairment) with monitoring. |
| Pediatric use | Not indicated for use in pediatric patients. Safety and efficacy not established. |
| Geriatric use | Use with caution in patients over 65 years due to limited data. No specific dose adjustment recommended, but consider increased risk of thromboembolic events and hyperkalemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| FDA category | Positive |
| Breastfeeding | Excreted in breast milk. M/P ratio not established. Use during breastfeeding not recommended due to potential adverse effects on milk production and infant hormonal balance. |
| Teratogenic Risk | Pregnancy category X. Contraindicated in pregnancy. First trimester: Increased risk of cardiovascular and limb defects. Second and third trimesters: Risk of fetal urogenital abnormalities, feminization of male fetuses. Associated with hypospadias and congenital heart defects. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
| Common Effects | osteoporosis prevention |
| Serious Effects |
["Renal impairment (creatinine clearance <50 mL/min)","Adrenal insufficiency","Hepatic impairment","History of or current thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected pregnancy","Undiagnosed abnormal uterine bleeding","Known or suspected carcinoma of the breast or personal history of breast cancer","Hypersensitivity to any component","Use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
| Precautions | ["Thrombotic disorders and other vascular problems","Liver disease","Hypertension","Gallbladder disease","Carbohydrate and lipid metabolic effects","Headache/migraine","Bleeding irregularities","Depression","Carcinoma of the breast and reproductive organs","Hereditary angioedema","Chloasma","Hyperkalemia (due to drospirenone's antimineralocorticoid effect, especially in patients with renal impairment, hepatic impairment, or adrenal insufficiency)"] |
Loading safety data…
| Fetal Monitoring | Not applicable in pregnancy (contraindicated). In non-pregnant women: measure blood pressure 3 months after initiation, monitor serum potassium in predisposed conditions (renal impairment, adrenal insufficiency, hepatic dysfunction). |
| Fertility Effects | Reversible inhibition of ovulation. Can impair fertility during use. Return to normal fertility upon discontinuation. |